Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting
UTRECHT, The Netherlands, 2016-04-15 23:09 CEST (GLOBE NEWSWIRE) --
Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), today announced a scheduled poster presentation at the American Association for Cancer Research (AACR) 2016 Annual Meeting being held April 16-20, 2016 in New Orleans.
Merus will be presenting interim clinical data for its lead bispecific antibody candidate MCLA-128 from a first-in-human Phase 1/2 clinical trial. MCLA-128 is a novel full-length Immunoglobulin G (IgG) bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) that is designed to bind to human epidermal growth factor receptors, HER2 and HER3, present on a variety of solid tumor cells. Merus will present on the open-label dose escalation phase (Part 1) of the Phase 1/2 clinical trial. The primary objectives in Part 1 of the clinical trial are to determine a maximum tolerated dose and to establish the recommended dose for a Phase 2 clinical trial of MCLA-128; the secondary objectives are to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity.
“We believe the interim data we are presenting from Part 1 of this first clinical trial of MCLA-128 demonstrates a favorable safety profile and early signs of anti-tumor activity,” said Setareh Shamsili, MD, PhD, Chief Medical Officer of Merus. “In Part 2 of this clinical trial, we will continue to evaluate MCLA-128 for safety and efficacy in patients with selected tumor types and patients with HER2 amplification in other tumor types. We expect to report top-line data from both parts of this trial in the first half of 2017.”
“We are proud to have reached this milestone for the company, the MCLA-128 program and our Biclonics platform,” commented Ton Logtenberg, PhD, Chief Executive Officer of Merus. “The timely delivery of this clinical milestone follows the rapid progression of MCLA-128 through preclinical discovery and manufacturing, which we believe validates the strength of the Biclonics platform. We look forward to the next part of this clinical trial while we continue to use the Biclonics platform to build a pipeline of therapeutics that we believe has the potential to address the unmet needs of cancer patients.”
The details for the poster presentation are as follows:
Poster Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2/HER3, in Patients with Solid Tumors
Date & Time: Monday, April 18, 2016, 1:00 PM – 5:00 PM CDT
Abstract Number: CT050
Session ID: PO.CT01.01. Phase 1 Clinical Trials 1
Location: Section 13
Summary: In Part 1, the dose escalation phase of this Phase 1/2 clinical trial, patients with advanced solid tumors that are relapsed or refractory to at least one prior regiment of available standard treatment or for whom no curative therapy is available were enrolled. MCLA-128 was administered every 3 weeks (q3w) as an intravenous infusion over 60-120 minutes. Toxicities were assessed at escalating dose levels. Twenty-eight patients received MCLA-128 in 9 dose escalation cohorts (in a range of 40 mg to 900 mg flat dose).
A maximum tolerated dose was not reached at the dose level of 900 mg. The cumulative safety and available PK data, along with the aid of a PK simulation study, were used to support a recommended dose for a Phase 2 clinical trial of 750 mg q3w, administered over 120 minutes. We believe encouraging signs of anti-tumor activity (assessed by RECIST v.1.1) were observed. Three patients remain in the trial to date, including one metastatic non-small cell lung cancer patient who is experiencing an ongoing partial response after more than 9 months, one metastatic gastroesophageal junction cancer patient with stable disease after more than 5 months, and one metastatic colorectal cancer patient with stable disease after more than 6 months. In addition, one metastatic breast cancer patient with stable disease received 5 months of MCLA-128 treatment before disease progression. MCLA-128 was well-tolerated with a favorable safety profile in patients with advanced tumors treated at doses up to 900 mg q3w. The expansion phase (Part 2) of the clinical trial is ongoing at the recommended Phase 2 dose of 750 mg q3w, enrolling patients with selected tumor types with HER2 amplification.
About Merus B.V.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus’ second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Shelley Margetson - firstname.lastname@example.org
+31 (0)30 253 8800
Eliza Schleifstein - email@example.com
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00 | Pressemelding
LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate
Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00 | Pressemelding
New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment
BroadSoft Announces New Integrated and Intelligent Cloud Communication and Collaboration Experiences23.10.2017 07:30 | Pressemelding
Upgrades deliver on the BroadSoft Business cloud unified communication vision to deliver intuitive, consistent client experiences across the entire suite and reinvent workflow efficiencies PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT) a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today unveiled several enhancements to its BroadSoft Business portfolio at its annual user conference, BroadSoft Connections. Now leveraging a microservices architecture, BroadSoft Business offers updated app experiences and next-generation capabilities across the BroadSoft Business applications, UC-One, Team-One and CC-One. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0df82bc5-5481-4429-9586-bba075849626 Business users today are overwhelmed with managing their workfl
BroadSoft Business Cloud PBX, Team Collaboration and Contact Center Apps Now Available for Multinational Enterprises23.10.2017 07:30 | Pressemelding
New, localized data centers offer multinational enterprise customers secure, multi-language calling and collaboration between global offices via a single, borderless BroadCloud platform PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT) a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today announced its BroadSoft Business cloud communication suite is available worldwide via several new BroadCloud ® data centers throughout EMEA and APAC. This expansion allows multinational enterprises to rely on a single provider across their international locations to collaborate with peers and customers around the globe, while meeting full regulatory and security compliance across different countries. A recent McKinsey Global Institute 2016 report noted that cross-border bandwidth is projected to increase nine times over the next
Powered by BroadSoft Channel Program Introduces New Digital Customer Lifecycle Platform and Services to Enhance Revenue Growth23.10.2017 07:30 | Pressemelding
Powered by BroadSoft now includes more than 100 global channel partners to realize the full potential of the cloud unified communication and collaboration market opportunity PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT) a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS) today announced the addition of new digital customer lifecycle management tools including the BroadCloud® Channel Support System (CSS) and three new services: BroadSoft go-to-market services, BroadSoft onboarding services and BroadSoft adoption services. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b86c0264-fb6d-44fd-a7ae-38bba426e281 Powered by BroadSoft, which launched at BroadSoft Connections last year, currently supports 116 channel partners across the globe, v
BroadSoft Hospitality Enhanced with Mobile UC-One Workstream Collaboration Capabilities to Amplify Productivity and Guest Experiences23.10.2017 07:30 | Pressemelding
New BroadSoft Hospitality features integrated into UC-One Connect allow hotels to access, respond to and act on guest requests in real-time, no matter where they are on the property PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT), a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today announced new UC-One mobile features for the BroadSoft Hospitality solution. The new features provide hotels with the ability to control the guest experience at any time from the UC-One mobile client. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1fcfab75-3ddf-4c39-93f1-7c3e74458115 This new offering is a continuation of ongoing efforts by BroadSoft to help hotels deliver a greater level of experience to their guests. The mobile integration allows front desk hotel
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom